Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S.

We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment

OMN6 demonstrates safety and tolerability at clinically significant dose levels   JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech &

The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria.  Our Scientists at Omnix

Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70.  At Omnix, we are working hard to build

New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives  JERUSALEM, Israel, April 12, 2022 — Omnix

Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR) JERUSALEM, Israel, March 16, 2022 — Omnix Medical, a biopharmaceutical company developing

To encourage EU Member States to actively contribute to exchanges on AMR in the co-legislative process, the BEAM Alliance relies on a network of National

Omnix Medical is honored to have earned a recent grant award from the Israel Innovation Authority to support continued development of new and effective lifesaving

By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and

Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) Clinical trial preparations of OMN6 under way Jerusalem, Israel — Omnix Medical, a Jerusalem-based biopharmaceutical

New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we

Une nouvelle technologie inspirée par la nature pour éradiquer de dangereuses bactéries multirésistantes. (A new technology inspired by nature to eradicate dangerous multiresistant bacteria.)

Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme.

Omnix Medical, a Jerusalem-based biopharmaceutical company, has completed an $8.5 million round led by Tal Capital (US) and Entrée Capital (IL) in association with UK based businessman Vincent Chenkwiz of CBG Group (UK) and joined by Xenia Ventures (IL) VLX Ventures (IL) and the Israeli Innovation Authority (IIA). Since its inception, the company has raised $10M.

Omnix Medical, a biotech company dedicated to the development of novel antimicrobial pharmaceuticals against drug-resistant bacteria, today announced the appointment of Antonius (Toni) Schuh, Ph.D.,

Offering new hope for patients suffering from drug resistant infections SAN FRANCISCO, Calif., January 3, 2020 – Omnix Medical has scheduled a company presentation at

” ..Omnix Medical, a Biotech company located in Jerusalem and dedicated to the development of novel antimicrobial drugs, is very happy to announce that: OMN6,